Evidence map›Paper›PMID 30741545›Full record

ArticleJournal of medicinal chemistry2019

Discovery of Polypharmacological Melanocortin-3 and -4 Receptor Probes and Identification of a 100-Fold Selective nM MC3R Agonist versus a μM MC4R Partial Agonist.

Katlyn A Fleming, Katie T Freeman, Mike D Powers, Radleigh G Santos, Ginamarie Debevec, Marc A Giulianotti, Richard A Houghten, Skye R Doering, Clemencia Pinilla, Carrie Haskell-Luevano

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Katlyn A FlemingDepartment of Medicinal Chemistry , University of Minnesota , Minneapolis , Minnesota 55455 , United States.
Katie T FreemanDepartment of Medicinal Chemistry , University of Minnesota , Minneapolis , Minnesota 55455 , United States.
Mike D PowersDepartment of Medicinal Chemistry , University of Minnesota , Minneapolis , Minnesota 55455 , United States.
Radleigh G SantosTorrey Pines Institute for Molecular Studies , Port St. Lucie , Florida 34987 , United States.
Ginamarie DebevecTorrey Pines Institute for Molecular Studies , Port St. Lucie , Florida 34987 , United States.
Marc A GiulianottiTorrey Pines Institute for Molecular Studies , Port St. Lucie , Florida 34987 , United States.
Richard A HoughtenTorrey Pines Institute for Molecular Studies , Port St. Lucie , Florida 34987 , United States.
Skye R DoeringDepartment of Medicinal Chemistry , University of Minnesota , Minneapolis , Minnesota 55455 , United States.
Clemencia Pinilla
Carrie Haskell-LuevanoDepartment of Medicinal Chemistry , University of Minnesota , Minneapolis , Minnesota 55455 , United States.ORCID 0000-0002-6783-5972
University of Minnesota · USTorrey Pines Institute For Molecular Studies · US

Funding

Melanocortin Selective LigandsR01DK091906 · NIDDK · UNIVERSITY OF MINNESOTA · PI HASKELL-LUEVANO, CARRIE · 2012 to 2015
$1.8M
NIDDK NIH HHS R01 DK091906
6 · The paper itself

Abstract

The centrally expressed melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R, respectively) are established targets to treat diseases of positive- and negative-energy homeostasis. We previously reported [ Doering , S. R. ; J. Med. Chem. 2017 , 60 , 4342 - 4357 ] mixture-based positional scanning approaches to identify dual MC3R agonist and MC4R antagonist tetrapeptides. Herein, 46 tetrapeptides were chosen for MC3R agonist screening selectivity profiles, synthesized, and pharmacologically characterized at the mouse melanocortin-1, -3, -4, and -5 receptors. Substitutions to the tetrapeptide template were selected solely based on MC3R agonist potency from the mixture-based screen. This study resulted in the discovery of compound 42 (Ac-Val-Gln-(pI)DPhe-DTic-NH

Indexed as

Drug DiscoveryMolecular ProbesAnimalsMicePolypharmacologyReceptor, Melanocortin, Type 3Receptor, Melanocortin, Type 4Structure-Activity RelationshipMc3r protein, mouseMC4R protein, mouseMolecular ProbesReceptor, Melanocortin, Type 3Receptor, Melanocortin, Type 4

Identifiers

PMID30741545
PMCPMC6463894
OpenAlexW2912622400

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.